Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer

Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer

Brief Summary:

This is a Phase 1a/b, multicenter, open-label, dose escalation (1a) and dose expansion (1b) study. The purpose of this study is to measure safety, tolerability, and preliminary efficacy with the combination of tipifarnib with osimertinib in patients with advanced/metastatic EGFR-mutated non-small cell lung cancer.

Condition or disease Intervention/treatment Phase
NSCLC Drug: Tipifarnib Drug: Osimertinib Phase 1

Expanded Access: An investigational treatment associated with this study is available outside the clinical trial.   More info …

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

January 23, 2023Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments